Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Feb 4, 2015
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.887 billion during the fourth quarter ended December 31, 2014, compared to the company's guidance range for the quarter of $1.875 to...
-
Feb 3, 2015IndustryWeek recognition highlights manufacturing excellence
The Boston Scientific (NYSE: BSX) Maple Grove Operations facility, Maple Grove, Minn., has been named a 2014 Best Plants winner by IndustryWeek magazine. IndustryWeek annually recognizes...
-
Feb 2, 2015
Boston Scientific Corporation (NYSE: BSX) announces the launch and first U.S. implant of its line of Extended Longevity (EL) implantable cardioverter defibrillators (ICD), including DYNAGEN™ EL...
-
Jan 20, 2015
Marlborough, Mass. (January 20, 2015) – Boston Scientific Corporation (NYSE: BSX), a global medical device company headquartered in Marlborough, Massachusetts, will co-sponsor the 2015...
-
Jan 15, 2015
Boston Scientific Corporation (NYSE: BSX) will host and webcast an Investor Day business review meeting for the investment community on Friday, May 1, 2015. The meeting and webcast are scheduled...
-
Jan 7, 2015
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year ended December 31, 2014 on...
-
Dec 22, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 in San Francisco. Mike Mahoney, president...
-
Dec 18, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs CEOs Unscripted Healthcare Conference on Tuesday, January 6, 2015 in Boston. Mike Mahoney, president and...
-
Dec 12, 2014Significant Relief Achieved Using Advanced Illumina™ 3D Programming Software
New retrospective data evaluating the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate that the device provided sustained, highly...
-
Nov 19, 2014
Boston Scientific has scored the highest rating of 100 percent in the Human Rights Campaign (HRC) Foundation's 2015 Corporate Equality Index (CEI). The top mark distinguishes the company as one of...
-
Nov 19, 2014EVOLVE II Trial Represents the First Successful U.S. Pivotal Trial of a Bioabsorbable Polymer Stent
In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific (NYSE: BSX) SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent...
-
Nov 17, 2014
Boston Scientific Corporation (NYSE: BSX) announces the completion of the first U.S. procedures performed with the Symphion System, designed for the hysteroscopic removal of interuterine fibroids...
-
Nov 13, 2014New CPT Category I Code Facilitates Processing for U.S. Hospitals and Physicians
Boston Scientific Corporation (NYSE: BSX) announced that its subcutaneous implantable defibrillator (S-ICD System™) will have designated Current Procedural Terminology (CPT®) Category I codes...
-
Nov 5, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Stifel Healthcare Conference on Tuesday, November 18, 2014 in New York City. Dan Brennan, executive vice president...
-
Nov 4, 2014Event will be held in Chicago, Site of the 2014 American Heart Association Scientific Sessions
Boston Scientific Corporation (NYSE: BSX) today announced that it will be holding an analyst event on November 19, 2014 to provide an update on company interventional cardiology initiatives and...
-
Nov 3, 2014Data Will Focus on Long-Term Back Pain Relief Using the Boston Scientific Precision Spectra™ Spinal Cord Stimulator (SCS) System and Highlight Research on Stimulation Waveforms
Boston Scientific Corporation (NYSE: BSX) is reinforcing the company's commitment to developing innovative and effective therapies in neuromodulation. The company will present data on key clinical...
-
Oct 30, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Credit Suisse Annual Healthcare Conference on Tuesday, November 11, 2014 in Phoenix, AZ. Dan Brennan, executive...
-
Oct 22, 2014
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.846 billion during the third quarter ended September 30, 2014, compared to the company's guidance range for the quarter of $1.790 to...
-
Oct 21, 2014World's First 32-contact SCS Surgical Leads Designed to Provide More Focused Pain Relief for Patients with Chronic Pain
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) and CE Mark approval for the CoverEdge™ 32 and CoverEdge™ X 32 Surgical Leads, the world's first...
-
Oct 20, 2014First Patient Enrolled in PLATINUM Diversity Trial Evaluating Performance in Women, Black Americans, Latinos/Hispanics, Native Americans and Alaska Natives with Coronary Artery Disease
As part of its commitment to innovation and improving patient outcomes, Boston Scientific Corporation (NYSE: BSX) has initiated the PLATINUM Diversity trial to evaluate the clinical performance of...
-
Oct 16, 2014The innovative devices allow pacemaker patients access to full body MRI scans in 1.5 Tesla and 3.0 Tesla systems
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the ACCOLADETM pacemaker family. When implanted with the company's INGEVITYTM leads, ACCOLADE pacemakers are the first...
-
Oct 8, 2014Comprehensive Clinical Data from Randomized Trials Reviewed
After reviewing updated data and analysis for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, the U.S. Food and Drug Administration (FDA)...
-
Oct 1, 2014
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2014 on Wednesday, October...
-
Sep 23, 2014Data From REPRISE III Clinical Trial Designed to Support U.S. Regulatory Approval
Boston Scientific Corporation (NYSE: BSX) has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus™ Valve System in patients with...
-
Sep 17, 2014Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement...